Since GC376 shows broad-spectrum activity against coronavirus, early on during the pandemic of 2020 it was suggested as a potential treatment for COVID-19.
In response to the crisis, researchers at the University of Arizona published in vitro research indicating GC376 is highly active against 3CLpro in SARS-CoV-2 (the coronavirus which causes COVID-19).
Another group of virologists at the University of Alberta lead by D. Lorne Tyrrell then released a separate publication confirming GC376's activity against 3CLpro in SARS-CoV-2 and also indicating GC376 had a potent antiviral effect.
The next day, Columbia University's Zuckerman Institute hosted a COVID-19 Virtual Symposium which released research led by David Ho and characterized GC376 as "the most promising" protease inhibitor under investigation in Ho's lab because GC376 was the "most potent" and reached "complete viral inhibition" in a culture of cells infected with SARS-CoV-2.
Since GC376 shows broad-spectrum activity against coronavirus, early on during the pandemic of 2020 it was suggested as a potential treatment for COVID-19. In response to the crisis, researchers at the University of Arizona published in vitro research indicating GC376 is highly active against 3CLpro in SARS-CoV-2 (the coronavirus which causes COVID-19). Another group of virologists at the University of Alberta lead by D. Lorne Tyrrell then released a separate publication confirming GC376's activity against 3CLpro in SARS-CoV-2 and also indicating GC376 had a potent antiviral effect. The next day, Columbia University's Zuckerman Institute hosted a COVID-19 Virtual Symposium which released research led by David Ho and characterized GC376 as "the most promising" protease inhibitor under investigation in Ho's lab because GC376 was the "most potent" and reached "complete viral inhibition" in a culture of cells infected with SARS-CoV-2.
GC376